Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.
FDA’s flashing green light boosts novel drug approvals
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.
